Fax: (503) 494-6197
Toward predictors of survival in castration-resistant prostate cancer†
Article first published online: 9 MAR 2011
Copyright © 2011 American Cancer Society
Volume 117, Issue 17, pages 3882–3884, 1 September 2011
How to Cite
Graff, J. N. and Beer, T. M. (2011), Toward predictors of survival in castration-resistant prostate cancer. Cancer, 117: 3882–3884. doi: 10.1002/cncr.25986
See referenced original article on pages 3963-71, this issue.
- Issue published online: 19 AUG 2011
- Article first published online: 9 MAR 2011
- Manuscript Accepted: 18 JAN 2011
- Manuscript Revised: 14 JAN 2011
- Manuscript Received: 3 JAN 2011
Overall survival is a widely accepted endpoint in phase 3 clinical trials of castration-resistant prostate cancer (CRPC). However, the use of this endpoint is becoming more difficult as more agents are shown to improve survival in patients with CRPC. This editorial describes the commonly used surrogates for overall survival in CRPC with a special emphasis on radiographic response.